



(51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61P 35/00* (2006.01)
A61K 38/17 (2006.01)

(21) **International Application Number:**
PCT/US2019/052022

(22) **International Filing Date:**
19 September 2019 (19.09.2019)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
62/733,623 19 September 2018 (19.09.2018) US
62/733,625 19 September 2018 (19.09.2018) US
62/818,058 13 March 2019 (13.03.2019) US

(71) **Applicant: ALPINE IMMUNE SCIENCES, INC.**
[US/US]; 201 Elliott Avenue West, Suite 230, Seattle,
Washington 98119 (US).

(72) **Inventors: SWANSON, Ryan;** 201 Elliott Avenue West,
Suite 230, Seattle, Washington 98119 (US). **MAURER,**
Mark F.; 201 Elliott Avenue West, Suite 230, Seattle,
Washington 98119 (US). **PENG, Stanford L.;** 201 Elliott

Avenue West, Suite 230, Seattle, Washington 98119 (US).
YANG, Jing; 201 Elliott Avenue West, Suite 230, Seattle,
Washington 98119 (US). **SWIDEREK, Kristine M.;** 201
Elliott Avenue West, Suite 230, Seattle, Washington 98119
(US).


(74) **Agent: POTTER, Karen et al.;** Morrison & Foerster LLP,
12531 High Bluff Drive, Suite 100, San Diego, California
92130-2040 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) **Title:** METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS

FIG. 1B



(57) **Abstract:** Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of oncological conditions. Compositions and methods for making and using such proteins are provided.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

14 May 2020 (14.05.2020)